Compare Amplify Transformational Data Sharing ETF (BLOK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Sanofi SA — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.75, while Sanofi SA trades at $43.46 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Amplify Transformational Data Sharing ETF pays none, and Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| BLOK | SNY | |
|---|---|---|
52-Week High | $74.10 | $52.34 |
52-Week Low | $47.36 | $41.33 |
Market Cap | — | $104.30B |
Sector | — | Health |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.12, up 1.76% with a bearish technical signal from moving averages but neutral oscillators. Support lies at $59 and resistance at $61. The ETF's financial ratios are not disclosed, and a small dividend of $0.08 is scheduled for June 2026. Recent news highlights institutional trimming and focus on AI infrastructure holdings.
Outlook remains cautious due to bearish technicals and lack of fundamental data. Risks include sector volatility and institutional selling. Opportunities may arise from AI-driven growth in portfolio companies, but investors should await clearer financial metrics for valuation.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
